Assessment of the efficacy of antihistamine drugs in complex treatment of chronic itchingdermatoses
- Authors: Murashkin NN1, Gluzmin MI1, Materikin AI1, Murashkin NN1, Gluzmin MI1, Materi kin AI1
-
Affiliations:
- Issue: Vol 87, No 4 (2011)
- Pages: 84-87
- Section: Articles
- Submitted: 11.03.2020
- Published: 15.08.2011
- URL: https://vestnikdv.ru/jour/article/view/1050
- DOI: https://doi.org/10.25208/vdv1050
- ID: 1050
Cite item
Full Text
Abstract
The authors give a review of current concepts of mechanisms of skin itching development for different types of chronic
dermatoses. The authors also present the results of a study aimed at assessing the efficacy of different 2nd generation
antihistamine drugs used for complex treatment of 83 patients aged 14-73 suffering from different chronic itching
dermatoses (atopic dermatitis, eczema, pruritus, chronic urticaria, progressing psoriasis, lichen acuminatus, contact
allergic dermatitis).
The authors conclude that Glencet (levocetirizine) used in a complex therapy of dermatoses accompanied with itching
can efficiently arrest both subjective itching sensations and objective clinical symptoms of the diseases as well as reliably
(р < 0.001) reduce the term of inpatient care by 4.8 ± 2.3 on average.
Glencet (levocetirizine) is a drug of choice among the 2nd generation antihistamine drugs used for treatment of chronic
skin diseases accompanied with itching.
dermatoses. The authors also present the results of a study aimed at assessing the efficacy of different 2nd generation
antihistamine drugs used for complex treatment of 83 patients aged 14-73 suffering from different chronic itching
dermatoses (atopic dermatitis, eczema, pruritus, chronic urticaria, progressing psoriasis, lichen acuminatus, contact
allergic dermatitis).
The authors conclude that Glencet (levocetirizine) used in a complex therapy of dermatoses accompanied with itching
can efficiently arrest both subjective itching sensations and objective clinical symptoms of the diseases as well as reliably
(р < 0.001) reduce the term of inpatient care by 4.8 ± 2.3 on average.
Glencet (levocetirizine) is a drug of choice among the 2nd generation antihistamine drugs used for treatment of chronic
skin diseases accompanied with itching.
Keywords
References
- Соколовский Е.В. Кожный зуд. Акне. Урогенитальная хламидийная инфекция. СПб.: «СОТИС» 1988; 3-67.
- Торопина Г.Г., Иванов О.Л., Львов А.Н. Инновационные методы нейрофизиологического исследования механизмов зуда у больных атопическим дерматитом. Росс. журн. кожн. и венерич. бол, 2009; 4: 28-31.
- O'Neill J.L., Chan Y.H., Rapp S.R. Differences in itch characteristics between psoriasis and atopic dermatitis patients: results of a webbased questionnaire. Acta Derm Venereol. 2011 Apr 29 [Epub ahead of print].
- Devalia J.L., de Vos C., Hanotte F. et al. A randomized double-blind crossover comparison among cetirizine, levocetirizine and UCB 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy 2001; 56: 50-7.
- Salmun L.M. Antihistamines in late-phase clinical development for allergic disease. Expert Opin Invest Drugs 2002; 11: 259-73.
- Гребенченко Е.И., Гущин К., Феденко Е.С. Механизм кожного зуда при атопическом дерматите. Рос. аллергол. журн. 2009; 3: 3-11.
- Эбаноидзе Т., Беридзе Л., Твалиашвили Г. Нейроанатомические и нейрофизиологические аспекты зуда в лечении атопического дерматита. Аллергология и иммунология, 2010; 11: 2: 92-93.
- Свирщевская Е.В., Матушевская Е.В., Матушевская Ю.И. Патофизиология зуда при некоторых дерматозах. Росс. журн. кожн. венерич. болезней. 2009; 1: 19-23.
- Chen C. Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine. Curr Med Chem 2008; 15 (21): 2173-2191.
- Львов А.Н., Грундманн С., Штендер С. Хронический зуд: старые проблемы, новые решения. Росс. журн. кожн. венерич. болезней, 2010; 4: 7-12.
- Klimek L. Levocetirizine: from scientific evidence to a potent modern-day treatment of today's allergic patients. Drugs Today (Barc) 2009 (Mar); 45 (3): 213-225.